louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05507788: Multicell Air Cushions: Sitting Posture and Limits of Stability
Official title: Wheelchair Seating: An Assessment of Multicell Air Cushions on Sitting Posture and Limits of Stability
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wheelchairs
Self-Help Devices
Posture
Sitting Position
Limits of Stability
Balance
Lead sponsor: Jonkoping University
Sponsor class: OTHER
First posted: 2022-08-19
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The convenience sample of 15 individuals will each complete the test protocol under the 3 seating conditions in random order.
Primary purpose: TREATMENT

Brief summary: The study's aim is to assess the sitting and dynamic postural control of stability of wheelchair users who have compromised postural control and risk of ulcers while using individually adjusted multi-cell air cushions with and without individual cell-locking function and variable depths.


Eligibility criteria: Inclusion Criteria:

* individuals who use a wheelchair
* have used a wheelchair for no less than 2 years
* score from 3-6 on the Functional Independence Measure
* not currently inpatients or those currently accessing acute care for concomitant health-related issues

Primary outcomes:
measure: Reach distance
timeFrame: Day 1
measure: Accuracy
timeFrame: Day 1
measure: Time
timeFrame: Day 1
measure: total path length of Center of Pressure
timeFrame: Day 1
measure: mean velocity of Center of Pressure
timeFrame: Day 1
measure: pressure-distribution between the seating surface and the two foot Force-sensing arrays
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Jönköping
country: Sweden
facility: Jönköping University
Study officials:
affiliation: Jonkoping University
name: David F Rusaw, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01008488: Antibiotic Therapy of Acute Uncomplicated Colonic Diverticulitis
Official title: Is Antibiotic Therapy Mandatory for Treatment of Uncomplicated Acute Colonic Diverticulitis: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonic Diverticulitis
Keywords: colonic diverticulitis
diverticular disease
antibiotic therapy
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: Landstinget i Värmland
First posted: 2009-11-05
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate if antibiotic therapy is necessary for treatment of uncomplicated colonic diverticulitis.

The hypothesis is that Patients with acute uncomplicated colonic diverticulitis will recover the condition without antibiotic therapy and the lack of antibiotic therapy will not lead to complications.

The patients will be randomized to conservative treatment with and without antibiotic therapy.


Eligibility criteria: Inclusion Criteria:

* adults with CT sign of acute colonic uncomplicated diverticulitis
* elevated CRP and LPK
* Temp.38c or more

Exclusion Criteria:

* patients with peritonitis, sepsis or CT- sign of complicated diverticulitis with abscesses or free abdominal air
* pregnancy
* immunological incompetence and immunosuppressive therapy

Primary outcomes:
measure: discharge without complications +/- antibiotic therapy
timeFrame: Within 30 days after discharge
Secondary outcomes:
measure: to evaluate length of hospital stay, cost and late complications
timeFrame: one year after admission
Other outcomes:
Locations:
city: Västerås
country: Sweden
facility: The Central Hospital
state: Västmanland
Study officials:
affiliation: Center of Clinical Research, Västerås
name: Kenneth Smedh
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chabok A, Pahlman L, Hjern F, Haapaniemi S, Smedh K; AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg. 2012 Apr;99(4):532-9. doi: 10.1002/bjs.8688. Epub 2012 Jan 30.
Clinical trial NCT00585988: A Clinical Investigation of Recovery Following Hip Resurfacing or Total Hip Arthroplasty
Official title: Functional Recovery Following Hip Resurfacing or Total Hip Arthroplasty in Patients Matched By Age, Gender, and Activity Level
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Osteoarthritis
Rheumatoid Arthritis
Arthritis
Traumatic Arthritis
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
First posted: 2008-01-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to compare early functional outcomes in patients undergoing hip resurfacing and total hip arthroplasty with the M2a-Magnum™ using more objective measures of function.


Eligibility criteria: Inclusion Criteria:

* Patients requiring hip arthroplasty

Exclusion Criteria:

* Patients with sensory, neurological, or general health conditions that alter perception of their limb in space
* Patients with vestibular disorders

Primary outcomes:
measure: Functional Tests
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07015788: Open -Label,Cross Over Trail Evaluating the Glycemic Impact of Peach Varieties in Healthy Adullts
Official title: Open -Label,Cross Over Trail Evaluating the Glycemic Impact of Peach Varieties in Healthy Adullts
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Blood Glucoe
Keywords: glycemic index
glycemic load
Lead sponsor: Rehman Medical Institute - RMI
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate the effect of different peach varieties on the glycemic index (GI) in healthy adult participants. While peaches are generally classified as low-GI fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. By assessing and comparing the GI values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

Detailed description: This study aims to evaluate the effect of different peach varieties on the glycemic index (GI) in healthy adult participants. While peaches are generally classified as low-GI fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. By assessing and comparing the GI values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

Eligibility criteria: Inclusion Criteria:• Healthy male and female adults aged 18-50 years

* BMI between 18.5-24.9 kg/m²
* Normal fasting blood glucose (\<100 mg/dL)
* Willingness to adhere to the study protocol Exclusion Criteria:• Diagnosed diabetes, metabolic syndrome, or any glucose metabolism disorder
* Use of medications or supplements that affect glucose levels
* Allergy to peaches or intolerance to test/reference foods
* Pregnant or breastfeeding women
* Smoking or use of recreational drugs

Primary outcomes:
measure: Glycemic Index
timeFrame: 2 hours post-consumption (per intervention)
Secondary outcomes:
measure: Incremental Area Under the Curve (iAUC) for Blood Glucose
timeFrame: 0-120 minutes post-consumption
measure: Peak Blood Glucose Concentration
timeFrame: 0-120 minutes post-consumption
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Rehman Medical Institue
state: KP
Study officials:
References:
citation: Basit et al. (2022). J Pak Med Assoc. (Health burden).
citation: IDF Diabetes Atlas 2021 (Pakistan ranked 3rd in diabetes cases).
Clinical trial NCT00939588: Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
Official title: An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypertension
Keywords: Aliskiren,
hypertension,
renin-angiotensin-aldosterone system
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2009-07-15
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.


Eligibility criteria: Inclusion Criteria:

* Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension
* Patients who are eligible and able to participate in the study

Exclusion criteria:

* Severe hypertension or secondary form of hypertension.
* Serum potassium \> 5.1 mEq/L (mmol/L)
* Heart failure
* Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
* Uncontrolled or life-threatening arrythmia

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone
timeFrame: 56 days
Secondary outcomes:
measure: Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II
timeFrame: 56 days
measure: Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure
timeFrame: 56 days
measure: Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan
timeFrame: 56 days
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT00894088: Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions
Official title: A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prophylaxis of Organ Rejection
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2009-05-06
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Mycophenolate Mofetil 500 mg tablets under fasted conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to mycophenolate mofetil or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: baseline, 2-period, 14 day washout
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: CEDRA Clinical Research
state: Texas
Study officials:
affiliation: CEDRA Clinical Research
name: William Allan Alexander, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04629807: Anterior Gen Plus Study
Official title: The Anterior Gen Plus Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Spine Fusion
Lead sponsor: SeaSpine, Inc.
Sponsor class: INDUSTRY
First posted: 2020-11-16
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A clinical study evaluating patients treated with the Demineralized Bone Matrix (DBM) as compared to a Cellular Bone Matrix (CBM) in anterior lumbar interbody fusion.

Detailed description: A prospective, single-center, clinical study evaluating patients undergoing primary, contiguous 2-level ALIF without supplemental fixation treated with Demineralized Bone Matrix (DBM) as compared to a Cellular Bone Matrix (CBM).

Eligibility criteria: Inclusion Criteria:

* ≥18 years of age
* Requires anterior lumbar interbody (ALIF) fusion
* Are physically and mentally able and willing to return for the scheduled follow up visits, follow post-operative instructions
* Willing and able to sign study specific Informed Consent Form

Exclusion Criteria:

* Signs of acute infection
* Active malignancy and/or current chemotherapy
* Prior fusion at operative or adjacent level
* Institutionalized or a prisoner
* Documented history of alcohol or drug abuse
* Undergoing a worker's compensation case
* Pregnancy
* Participation in another research study involving another implant or drug that may affect the outcomes of this clinical study
* Any other condition that the Investigator determines is unacceptable for enrollment into this clinical study

Primary outcomes:
measure: Assessment of fusion for the DBM versus CBM cohorts
timeFrame: 12 months
Secondary outcomes:
measure: Serious Adverse Events (SAEs)
timeFrame: 24 Months
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
Study officials:
affiliation: Henry Ford Health System
name: Muwaffak Abdulhak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02953288: Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.
Official title: Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroid Cancer
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2016-11-02
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with thyroid nodule

Brief summary: To investigate the genetic mutations of patients with thyroid carcinoma and find molecular targets for therapy.

Detailed description: In previous studies, we have found highly prevalent TERT promoter mutations in aggressive thyroid cancers. So we plan to perform further research to investigate the genetic mutations of patients with thyroid carcinoma and find molecular targets for therapy.

Eligibility criteria: Inclusion Criteria:

* Patient with thyroid nodule

Exclusion Criteria:

* Coagulant function abnormality
* pregnant

Primary outcomes:
measure: Gene sequencing
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Endocrinology, Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
affiliation: Sanghai Tenth People's Hospital, Shanghai, China
name: Shen Qu
role: STUDY_DIRECTOR
References:
Clinical trial NCT01625585: Single Balloon Enterosocpy Obscure Gastrointestinal Bleeding Bleed
Official title: LONG-TERM OUTCOMES AFTER SINGLE-BALLOON ENTEROSCOPY IN PATIENTS WITH OBSCURE GASTROINTESTINAL BLEEDING
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obscure Gastrointestinal Bleeding
Keywords: Push-and-Pull Enteroscopy
Single-Balloon-Enteroscopy
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2012-06-21
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who underwent SBE at Washington University Medical Center/ Barnes Jewish Hospital prior to 1/1/2011 were eligible for inclusion. There was no control group as this was a retrospective cohort study.

Brief summary: The goal of the present study is to investigate the clinical outcomes of patients with gastrointestinal bleeding originating from the small intestine following diagnostic investigation with single balloon enteroscopy. We hypothesize that single balloon enteroscopy can arrive at a diagnosis and provide therapeutics in a majority of patients with gastrointestinal bleeding originating in the small intestine.

Detailed description: The small intestine has been, until recent years, a black box to gastroenterologists because it is difficult to see and reach. Radiological imaging provides little details of small intestinal mucosa. Capsule endoscopy, introduced in 2001, enables gastroenterologists to visualize the entire small intestine from within for the first time, but it is only a diagnostic tool. Single-balloon enteroscopy (SBE) is a new enteroscopy methods that use an overtube with one balloon or a spiral to help pleat bowel onto the endoscope and allow examination of the distal small bowel. This methods allow for biopsy, hemostasis, and other therapeutic interventions to be performed in the small bowel. Early reports have been promising; with 50-70% diagnostic yield for small bowel pathology reported in the literature. However, despite these promising results the impact SBE findings on patient outcomes is not clear.

Eligibility criteria: Inclusion Criteria:

* Patients with Obscure Gastrointestinal Bleeding undergoing SBE at Barnes Jewish Hospital

Exclusion Criteria:

* Less than 3 months of follow up after SBE
* The endoscope could not be advanced into the duodenum will be excluded.

Primary outcomes:
measure: Recurrence of obscure gastrointestinal bleeding following single balloon enteroscopy
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: St Louis
country: United States
facility: Barnes Jewish Hospital/ Washington University
state: Missouri
Study officials:
References:
Clinical trial NCT01102985: Women With Cancer: An Exercise Study to Promote Health
Official title: An Exercise Intervention to Improve Health in Postmenopausal Cancer Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Loss
Cancer
Keywords: exercise
physical activity
intervention
cancer survivor
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2010-04-13
Enrollment: 154
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the study is to evaluate the effect of an aerobic-resistance exercise program compared to a home based physical activity program on bone mass, body composition, metabolic risk factors and cardiovascular fitness in women with cancer who have completed therapy.

Detailed description: The proposed study will evaluate an endurance-resistive exercise intervention to attenuate the effects of menopause and cancer treatment (bone loss, increased body fat, decreased lean muscle mass, weight gain, decreased physical activity) in an at-risk population of female cancer survivors. Women with solid tumors (breast, gynecological, colo-rectal) and lymphoma who have completed primary and/or adjuvant therapy within the past three years and who are perimenopausal or early postmenopausal and any woman on an Aromatase Inhibitor will be recruited to participate in a randomized controlled trial (RCT) of a 12 month exercise intervention (N=75) versus a health promotion control group (N=75). The specific aims of the study are to: (1) examine the effects of an exercise intervention on bone mass (serum biomarkers, lumbar spine, hip DEXA) and body composition (whole body DEXA, weight, waist circumference), (2) examine the effect of an exercise intervention on metabolic risk factors (lipids, cholesterol, fasting glucose, insulin resistance, Hemoglobin A1-C, and blood pressure), and (3) examine the effects of an exercise intervention on functional status and cardiovascular fitness (exercise stress test).

Eligibility criteria: Inclusion Criteria:

* Female
* Cancer diagnosis
* Postmenopausal

Exclusion Criteria:

* Health condition contraindication to moderate physical activity

Primary outcomes:
measure: Bone mass-lumbar spine and hip (DEXA)
timeFrame: baseline, 12 months
Secondary outcomes:
measure: body composition-% fat mass, % lean muscle mass (whole body DEXA)
timeFrame: baseline, 6, 12 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: M. Tish Knobf, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Knobf MT, Jeon S, Smith B, Harris L, Thompson S, Stacy MR, Insogna K, Sinusas AJ. The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes. Heart Lung. 2017 Sep-Oct;46(5):375-381. doi: 10.1016/j.hrtlng.2017.06.001. Epub 2017 Aug 10.